TPST — Tempest Therapeutics Share Price
0.000.00%
Last trade - 00:00- $35.80m
- $15.32m
- 24
- 14
- 34
- 13
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.11 | ||
| Price to Tang. Book | 2.11 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -114.68% | ||
| Return on Equity | -289.26% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR). The ongoing global randomized Phase Ib/II trial of TPST-1120 combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, is in an ongoing Phase I combination trial in patients with endometrial cancer.
Directors
- Mike Raab CHM
- Tom Dubensky PRE
- Stephen Brady CEO (50)
- Nicholas Maestas CFO (41)
- Thomas Hoover OTH (52)
- Samuel Whiting OTH
- Christine Pellizzari DRC (53)
- Ronit Simantov DRC
- Tom Woiwode DRC
- Geoffrey Nichol IND (66)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- April 5th, 2011
- Public Since
- October 4th, 2012
- No. of Shareholders
- 78
- No. of Employees
- 17
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 25,207,792
- Address
- 2000 SIERRA POINT PARKWAY, SUITE 400, BRISBANE, 94005
- Web
- https://www.tempesttx.com/
- Phone
- +1 4157988589
- Auditors
- Ernst & Young LLP
Upcoming Events for TPST
Similar to TPST
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Tempest Therapeutics share price?
As of Today at 23:39 UTC, shares in Tempest Therapeutics are trading at $1.42. This share price information is delayed by 15 minutes.
How has the Tempest Therapeutics share price performed this year?
Shares in Tempest Therapeutics last closed at $1.42 and the price had moved by +132.79% over the past 365 days. In terms of relative price strength the Tempest Therapeutics share price has outperformed the S&P500 Index by +82.02% over the past year.
What are the analyst and broker recommendations for Tempest Therapeutics?
The overall consensus recommendation for Tempest Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Tempest Therapeutics dividend yield?
Tempest Therapeutics does not currently pay a dividend.
Does Tempest Therapeutics pay a dividend?
Tempest Therapeutics does not currently pay a dividend.
When does Tempest Therapeutics next pay dividends?
Tempest Therapeutics does not currently pay a dividend.
How do I buy Tempest Therapeutics shares?
To buy shares in Tempest Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Tempest Therapeutics?
As of the previous close price of $1.42, shares in Tempest Therapeutics had a market capitalisation of $35.80m.
Where are Tempest Therapeutics shares listed?
Here are the trading details for Tempest Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: TPST
What kind of share is Tempest Therapeutics?
Based on an overall assessment of its quality, value and momentum Tempest Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Tempest Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Tempest Therapeutics is $18.60. That is 1209.86% above the last closing price of $1.42.
Analysts covering Tempest Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.52 for the next financial year.
Find out moreWhat is the trend in the Tempest Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Tempest Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -67.24%.
As of the last closing price of $1.42, shares in Tempest Therapeutics were trading -56.27% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Tempest Therapeutics PE Ratio?
The Tempest Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.42.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Tempest Therapeutics?
Tempest Therapeutics' management team is headed by:
- Mike Raab - CHM
- Tom Dubensky - PRE
- Stephen Brady - CEO
- Nicholas Maestas - CFO
- Thomas Hoover - OTH
- Samuel Whiting - OTH
- Christine Pellizzari - DRC
- Ronit Simantov - DRC
- Tom Woiwode - DRC
- Geoffrey Nichol - IND